Editorials

Using monoamine oxidase type B inhibitors in Parkinson's disease

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7466.581 (Published 09 September 2004) Cite this as: BMJ 2004;329:581
  1. Yoav Ben-Shlomo, senior lecturer (Y.Ben-Shlomo@bristol.ac.uk),
  2. Kailash Bhatia, reader in clinical neurology (kbhatia@ion.ucl.ac.uk)
  1. Department of Social Medicine, University of Bristol, Bristol BS8 2PR
  2. Sobell Department of Movement Neuroscience, Institute of Neurology, London WC1N 3BG

    They are effective and safe, at least when used alone

    Despite the growth in new drugs for the treatment of idiopathic Parkinson's disease, high quality evidence from randomised controlled trials to guide clinicians on choosing the most appropriate therapy is scarce. Monoamine oxidase type B inhibitors (MAOBIs) have been available for about 30 years. Their popularity was boosted in the 1980s when researchers proposed that they may have a neuroprotective effect and hence alter the natural history of disease rather than merely provide symptomatic relief. Subsequently one report of increased mortality in patients given selegiline with levodopa dented this popularity.1 In this issue, Ives et al provide us with a useful summary of the trials on MAOBIs for the treatment of Parkinson's disease (p 593).2

    Of the 17 trials, most are short term studies—only seven have follow up data of over 18 months. In addition, most of the trials compare a MAOBI with placebo. These trials show that MAOBIs reduce symptoms compared with placebo and allow patients to be treated with lower doses of levodopa or delay the need to start taking levodopa. However, they provide no evidence that …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe